Highlights Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
38.82 ^USD	+0.13%		+8.92%	+542.72%

May. 01	Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI
May. 01	Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	Apr. 02	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701	Jan. 26	CI
Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)	Jan. 09	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting	Nov. 02	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Corbus Pharmaceuticals Holdings, Inc. to Present Latest Pre-Clinical Data on CRB-601 Av8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting	23-05-01	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-07	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI
Corbus Gets Exclusive Rights to Develop, Commercialize Clinical-Stage Nectin-4 Antibody Drug Conjugate CRB-701	23-02-13	MT
Corbus Pharmaceuticals Expands Oncology Pipeline with the Addition of A Clinical Stage Nectin-4 Targeting Antibody Drug Conjugate	23-02-13	CI
CSPC Unit Signs License Deal with Corbus Pharmaceuticals for Cancer Treatment Commercialization	23-02-12	MT
Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer 37th Annual Meeting	22-11-10	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Corbus Pharmaceuticals Gets Extension to Regain Compliance With Nasdaq Rule	22-07-07	MT
Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York	22-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Highlights

Filters